Last reviewed · How we verify
Cardizem (diltiazem)
Diltiazem (Cardizem) is a non-dihydropyridine calcium channel blocker approved in 1982. Unique among CCBs in providing both rate control and blood pressure reduction. Available generically in multiple formulations.
At a glance
| Generic name | diltiazem |
|---|---|
| Also known as | Cardizem, Tiazac, Dilacor |
| Sponsor | Generic (originally Tanabe Seiyaku) |
| Drug class | Calcium channel blocker (non-dihydropyridine, benzothiazepine) |
| Target | Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1982-11-05 (United States) |
Approved indications
- Angina pectoris
- Atrial fibrillation
- Hypertensive disorder
- Paroxysmal supraventricular tachycardia
- Prinzmetal angina
Common side effects
- Constipation
- Diarrhea
- Dry mouth
- Dyspepsia
- Headache
- Dizziness
- Fatigue
- Nausea
- Vomiting
- Anorexia
- Weight increase
- Thirst
Serious adverse events
- Congestive heart failure
- Syncope
- Asystole
- Myocardial infarction
- Angioedema
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Acute hepatic injury
- Hemolytic anemia
- Thrombocytopenia
Key clinical trials
- An Open-label, Non-randomized, Fixed Sequence Study Assessing the Pharmacokinetics of AZD7986 When Administered Alone and With Multiple Doses of Verapamil and Itraconazole or Diltiazem in Healthy Subj (Phase 1)
- Rate Control in Atrial Fibrillation (Phase 3)
- Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II: A Phase III Randomized Multicenter Clinical Trial of Blood Pressure Reduction for Hypertension in Acute Intracerebral Hemorrhage (Phase 3)
- Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study) (Phase 1)
- Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made By Pfizer, S.A. DE C.V., Versus Angiotrofin® 60 Mg Made By Amstrong Laboratorios De Mexico, S.A. DE C.V. Study In 26 Healthy Volu (Phase 1)
- Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas (NA)
- A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure (Phase 3)
- Multicenter, Double-blind, Randomized, Placebo-controlled Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia - A Phase (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cardizem CI brief — competitive landscape report
- Cardizem updates RSS · CI watch RSS
- Generic (originally Tanabe Seiyaku) portfolio CI